First-line Chemotherapy

Phase 2Small molecule

Roche

First-line Chemotherapy is one of 86 small molecule programs targeting Colorectal Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Colorectal CancerActive, not recruiting

Pancreatic CancerRecruiting

Colorectal CancerPreclinical

Active, not recruiting

Pancreatic CancerPhase 2

Recruiting

Competition

Competitive Landscape

306 competitors in Pancreatic Cancer

#DrugCompanyPhaseTrials

Medrol

Pfizer

Preclinical

1 2

Byetta

AstraZeneca

Preclinical

1 3

First-line Chemotherapy

Roche

Phase 2

1 4

Xylocaine

MMEDRx USA, Inc.

Preclinical

1 5

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 6

Ayvakit Sprinkle

MMemorial Sloan Kettering Cancer Center

Preclinical

1 7

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

1 8

Active Comparator

Moderna

Preclinical

1 9

Secretin-Ferring

Ferring

Preclinical

1 10

Sulfonylureas

Eli Lilly

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

PreclinicalRecruiting

Advanced Pancreatic Ductal Adenocarcinoma

NCT07408505

Q2 2032

Phase 2Recruiting

Pancreatic Cancer

NCT03322995

Clinical

Trials by Indication[1]

Small Cell Lung Cancer1 trial

Temozolomide as Maintenance Therapy Following Induction Chemotherapy in Extensive Stage Small Cell Lung Cancer

Unknown status·—·Phase 2/3·NCT02772107·132 enrolled

Gastric Cancer1 trial

Safety and Efficacy of Ginsenoside Rg3 in Combination With First-line Chemotherapy in Advanced Gastric Cancer

Unknown status·HHebei Tumor Hospital·Phase 2·NCT01757366·100 enrolled

Colorectal Cancer1 trial

PET/CT Scan as a Tool to Rationalize the Treatment of Patients With Advanced ColoRectal Cancer Undergoing First-line Medical Treatment

Unknown status·NNational Cancer Institute, Naples·N/A·NCT02618850·260 enrolled

Neoadjuvant Chemotherapy1 trial

Clinical Evaluation of Neoadjuvant Chemotherapy for Primary Malignant Sarcomas That Originate in Bone

Completed·PPeking University People's Hospital··NCT03742063·190 enrolled

Mantle Cell Lymphoma1 trial

A Study of MabThera (Rituximab) Plus Standard Chemotherapy in Patients With Previously Untreated Mantle Cell Lymphoma.

Completed· Roche logo

Roche·Phase 2·NCT00472420·48 enrolled

2 more indications

Pancreatic Cancer1 trial

Pancreatic Cancer Adaptive Neoadjuvant Chemotherapy Trial

Recruiting·MMedical College of Wisconsin·Phase 2·NCT03322995·125 enrolled

Advanced Pancreatic Ductal Adenocarcinoma1 trial

Efficacy and Safety of Nano-Megestrol Acetate in the Treatment of Anorexia-Cachexia Syndrome in Patients With Advanced Pancreatic Cancer: A Randomized, Controlled, Prospective Study

Recruiting·SShandong Cancer Hospital and Institute·Preclinical·NCT07408505·56 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for First-line Chemotherapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — First-line Chemotherapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for First-line Chemotherapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Roche company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Roche

First-line Chemotherapy

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Q2 2032

Trials by Indication[1]

Small Cell Lung Cancer1 trial

Gastric Cancer1 trial

Colorectal Cancer1 trial

Neoadjuvant Chemotherapy1 trial

Mantle Cell Lymphoma1 trial

Pancreatic Cancer1 trial

Advanced Pancreatic Ductal Adenocarcinoma1 trial

References

Drug Info

Quick Facts

Related News